Lenvatinib (off Label)
ACC-LEN14
Eisai (investigator studies) · Phase 2 · Completed · Enrollment 26
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|---|---|---|---|---|
| Lenvatinib 24 mg | R/M salivary ACC (n = 26 evaluable) | 24 mg | Single arm | n/r | objective response rate: 11.5%, primary analysismedian progression-free survival: 9.1 months, primary analysismedian overall survival: 27 months, primary analysis |